U.S. biotech companies debate relocating trials outside U.S., Reuters reports

Some U.S. biotech companies are debating on relocating their early-stage trials of new medicines outside the U.S. due to worries that layoffs and policy changes at the U.S. Food and Drug Administration by the Trump administration may lead to delays in regulatory reviews, Maggic Fick of Reuters reports, citing executives, investors, and consultants. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).